Method for regulating and controlling mosquito-borne virus infection by performing gene editing on mosquitoes
By partially knocking out the MAL1 gene of mosquitoes using CRISPR/Cas9 technology, the problem of poor effectiveness of traditional prevention and control strategies was solved, and the effect of reducing mosquito-articular virus infection was achieved. A model was provided for mosquito research and gene editing was demonstrated. clinical prospects.
Patent Information
- Application Number
- CN202411200125.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The existing mosquito-borne infectious disease prevention and control strategies have limited effectiveness in the face of mosquito resistance and environmental protection challenges. Traditional gene editing methods such as insect sterilization technology are unstable and require continuous release, and are not suitable for long-term applications.
CRISPR/Cas9 technology is used to partially knock out the MAL1 gene of mosquitoes to reduce the probability of mosquito-borne virus infection. By designing specific sgRNA and Cas9 nucleases for gene editing, gene knockout in mosquitoes or mosquito cells is achieved and viral load is reduced. , thereby preventing and treating mosquito-borne infectious diseases.
The decrease in viral load of mosquito infection by partial knockdown of MAL1 gene provides an effective method to prevent and treat mosquito-borne infectious diseases and provides a model for mosquito metabolism research and virus interaction. CRISPR/Cas9 technology is highly operational and low-cost , has clinical and application prospects.
Smart Images

Figure CN119040399A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a method for genetically editing mosquitoes to regulate mosquito-borne virus infection. Background Art
[0002] In recent years, the global incidence of mosquito-borne infectious diseases such as dengue fever, Zika, and malaria has increased significantly, posing a major challenge to public health. At present, there is no effective treatment plan or preventive vaccine for the vast majority of mosquito-borne infectious diseases during the internal latent period (human infection period). The main prevention and control strategy is to use a comprehensive prevention and control strategy based on environmental control and chemical control to cut off the mosquito-borne transmission route during the external latent period (mosquito infection period). However, with the increasing resistance of mosquitoes to pesticides and environmental protection issues, traditional prevention and control strategies have been challenged unprecedentedly. With the development of gene editing technology, research on mosquito immune biological blocking during the external latent period has become an important research direction for blocking the spread of mosquito-borne diseases today.
[0003] The CRISPR / Cas system is an acquired immune system of archaea. It cuts phage dsDNA through Cas protein, thereby destroying the phage genome and achieving the purpose of bacterial immunity to phage. CRISPR / Cas9 is a nuclease of the Cas system type II family. It can perform site-specific shearing between the third and fourth bases of the 5' direction of the genome NGG PAM structure, causing DNA double-strand breaks. The broken DNA chains are then reconnected together through the cell DNA repair mechanism non-homologous end joining and homologous repair, thereby achieving the editing of genomic DNA sequences. The emergence of CRISPR / Cas9 technology provides target-specific modification tools for conducting basic molecular biological research on mosquito physiology, biochemistry, development, host-pathogen relationships, and many other aspects, bringing new opportunities for the development of mosquito control technology.
[0004] In recent years, there have been some reports of using gene editing technology to avoid the spread of mosquito diseases. For example, researchers from the U.S. Army Cooperative Biotechnology Research Institute and the University of California, Santa Barbara used CRISPR / Cas9 gene editing tools to target genes related to male mosquito fertility and conducted a "sterilization" experiment on Aedes aegypti. They used a control method called insect sterility technology to breed many sterile male mosquitoes, and then released these insects. Female mosquitoes mated with sterile male mosquitoes, which would affect the survival of the former, thereby reducing the size of the next generation. However, this prevention and control method requires the continuous release of sterile male mosquitoes to suppress the number of mosquitoes, which is subject to many restrictions in practical applications. In addition, Brazil has also conducted similar "sterilization" experiments and found that after the gene-edited male Aedes aegypti mosquitoes that could theoretically reduce the number of Aedes aegypti populations were released into the environment, some of the mosquito offspring still reached sexual maturity and hybridized with local mosquitoes, which to some extent illustrates the instability and uncertainty of this method. Therefore, it is still necessary to find a new method for gene editing to prevent and control mosquito-borne infectious diseases. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a method for gene editing to prevent and control mosquito-borne viral infection for the extralatent period of mosquito-borne infectious diseases. By knocking out specific regions of the mosquito genome, the probability of mosquito-borne viral infection is reduced, providing a new direction for the treatment of such diseases.
[0006] The first object of the present invention is to provide a material for knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence for use in preparing a product for the prevention and treatment of mosquito-borne infectious diseases.
[0007] Furthermore, the partial knockout includes knocking out bases 73-99 of the gene sequence shown in SEQ ID NO.2 or its homologous sequence.
[0008] Furthermore, the substance for knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence includes CRISPR / Cas system, siRNA, shRNA, lentivirus-encapsulated sequence, etc.
[0009] Furthermore, the CRISPR / Cas system includes sgRNA and Cas9 nuclease. The Cas9 nuclease uses the recognition and positioning of the sgRNA to complete the cutting of the target gene fragment, resulting in the breakage of the target gene fragment in the mosquito or mosquito cell, thereby causing homologous recombination repair or non-homologous end joining, and then causing base frameshift mutation to achieve the purpose of gene knockout.
[0010] Furthermore, the sgRNA is designed with the sequence shown in SEQ ID NO.2 or a part of the sequence as the target.
[0011] Furthermore, the sgRNA is designed for the target shown in SEQ ID NO.3.
[0012] Furthermore, the sequence of the sgRNA is shown in SEQ ID NO.4.
[0013] Furthermore, the mosquito-borne infectious disease prevention and control includes but is not limited to the step of editing mosquitoes or mosquito cells to reduce the probability of viral infection.
[0014] Furthermore, the mosquito-borne infectious diseases include but are not limited to dengue fever, Zika, malaria, filariasis, Japanese encephalitis, echinococcosis, ascariasis, yellow fever, chikungunya fever, etc., that is, prevention and control of infections caused by dengue virus (DENV), Zika virus (ZIKV), malaria worms, filariasis, Japanese encephalitis virus, Echinococcus, ascariasis, yellow fever virus, chikungunya virus (CHIKV), etc.
[0015] The present invention uses CRISPR / Cas9 technology for the first time to knock out the MAL1 gene in Aedes aegypti, and obtains Aedes aegypti with a partial knockout of the MAL1 gene. Subsequent functional verification experiments show that compared with wild-type Aedes aegypti, the viral load of the Aedes aegypti with a partial knockout of the MAL1 gene after infection with the virus is reduced, indicating that substances that inhibit the MAL1 gene can be used to prevent and treat diseases transmitted by mosquitoes. At the same time, the Aedes aegypti with a partial knockout of the MAL1 gene prepared by the present invention can be used as an in vivo research model for the interaction between mosquitoes and viruses and the study of mosquito metabolism. At the same time, the success of the present invention in gene editing of mosquitoes also makes it possible to perform gene editing on more non-model organisms.
[0016] The second object of the present invention is to provide a drug for preventing or treating mosquito-borne infectious diseases (targeting the mosquito infection period), comprising a substance with the gene sequence shown in SEQ ID NO.2 or its homologous sequence knocked out or partially knocked out.
[0017] Furthermore, the mosquito-borne infectious disease drug is administered to mosquitoes or mosquito cells.
[0018] Furthermore, the substance for knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence includes CRISPR / Cas system, siRNA, shRNA, lentivirus-encapsulated sequence, etc.
[0019] Furthermore, the CRISPR / Cas system includes sgRNA and Cas9 nuclease.
[0020] Furthermore, the sgRNA is designed with the sequence shown in SEQ ID NO.2 or a part of the sequence as the target.
[0021] Furthermore, the sgRNA is designed for the target shown in SEQ ID NO.3.
[0022] Furthermore, the sequence of the sgRNA is shown in SEQ ID NO.4.
[0023] Furthermore, the mosquito-borne infectious disease drug is used in at least one of the following scenarios:
[0024] 1) Inhibit viral infection of mosquitoes or mosquito cells;
[0025] 2) Prevent and control diseases transmitted by mosquitoes;
[0026] 3) Prepare transgenic mosquitoes with reduced virus infection levels.
[0027] The third object of the present invention is to provide a method for reducing the level of viral infection in mosquitoes or mosquito cells, comprising the step of knocking out or partially knocking out (full length or a portion of a fragment) the gene sequence shown in SEQ ID NO.2 or its homologous sequence in mosquitoes or mosquito cells.
[0028] Furthermore, it includes the step of knocking out the AATGAAGATCTTGTTCCACTTCTAAG fragment or its homologous sequence in SEQ ID NO.2 in mosquitoes or mosquito cells.
[0029] Furthermore, the knockout method includes, but is not limited to, replacing the sequence comprising SEQ ID NO.5 with a sequence comprising SEQ ID NO.6, targeted knockout of the AATGAAGATCTTGTTCCACTTCTAAG fragment, etc.
[0030] Of course, the present invention also provides a method for preparing transgenic mosquitoes with reduced virus infection levels, comprising the following 1) or 2):
[0031] 1) Inhibit the activity of MAL1 protein in mosquitoes or reduce the content of MAL1 protein in mosquitoes;
[0032] 2) The DNA molecule in the mosquito corresponding to SEQ ID NO.5 in the sequence list is replaced with the DNA molecule corresponding to SEQ ID NO.6 in the sequence list.
[0033] Furthermore, the method further comprises the step of microinjecting the sgRNA and Cas9 nuclease into mosquito eggs. Preferably, the final concentration of the sgRNA is 20-60 ng / ul, and the final concentration of the Cas9 nuclease is 100-500 ng / ul.
[0034] Furthermore, the method also includes the step of using the gene-edited mosquito as a parent and hybridizing it with a wild-type or gene-edited mosquito.
[0035] In the present invention, the above-mentioned mosquitoes include but are not limited to Aedes aegypti.
[0036] The fourth object of the present invention is to provide a method for constructing a mosquito model or a mosquito cell model with a reduced level of viral infection, comprising the step of knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence on the mosquito or mosquito cell genome.
[0037] Furthermore, after the knockout step, the method further includes incubating the mosquito cells and then hybridizing the obtained individuals. The above incubation and hybridization steps can be repeated at least once until a knockout homozygote is obtained, that is, the mosquito model.
[0038] Furthermore, the specific method for constructing the mosquito model includes:
[0039] S1. Using a CRISPR system containing the sgRNA shown in SEQ ID NO.4 to treat mosquito eggs to obtain gene-edited mosquito eggs;
[0040] S2, hatching the mosquito eggs to obtain parent mosquitoes, hybridizing the parent mosquitoes with wild-type mosquitoes to obtain offspring mosquitoes;
[0041] S3, repeating step S2, and hybridizing the obtained offspring with the offspring until a knockout homozygote (a homozygote for knocking out bases 73-99 in SEQ ID NO.2) is obtained, thereby obtaining the mosquito model.
[0042] The fifth object of the present invention is to provide a mosquito model or a mosquito cell model obtained by the above construction method.
[0043] The sixth object of the present invention is to provide the application of the above-mentioned mosquito model or mosquito cell model in studying mosquito metabolism or mosquito-virus interaction.
[0044] By means of the above scheme, the present invention has at least the following advantages:
[0045] 1. The present invention discovers for the first time that MAL1 can regulate mosquito-borne viral infection. By knocking out or partially knocking out the MAL1 gene in mosquitoes or mosquito cells, the viral load in mosquitoes or mosquito cells can be reduced, thereby preventing and controlling mosquito-borne diseases.
[0046] 2. The present invention uses CRISPR / Cas9 technology for the first time to construct an Aedes aegypti with a partial knockout of the MAL1 gene. The obtained gene knockout strain is helpful for the study of genes, proteins or other functions in mosquitoes. It can be used as an individual mosquito model for mosquito metabolism research, and can also provide an individual mosquito model for mosquitoes to resist infection by pathogenic microorganisms. It can also provide an individual mosquito model for the related genes regulated by the MAL1 gene to affect the interaction between pathogenic microorganisms and mosquito-borne hosts.
[0047] 3. The CRISPR / Cas9 gene knockout technology used in the present invention is more effective than technical means such as gene silencing and interference. Due to its many advantages such as strong operability, low cost and wide application range, this technology is one of the gene therapy technologies with the most clinical and application prospects.
[0048] 4. The present invention utilizes gRNA primers to accurately and efficiently partially knock out the MAL1 gene.
[0049] 5. The mosquito egg microinjection method adopted in the present invention is more suitable for gene editing of insects, and a large number of gene-knockout mosquito strains can be obtained with one injection.
[0050] 6. The pupal skin genome screening method adopted by the present invention does not harm individual mosquitoes and can quickly realize the screening of knockout strain mosquitoes. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] In order to make the contents of the present invention more clearly understood, the present invention is further described in detail below based on specific embodiments of the present invention in conjunction with the accompanying drawings.
[0052] Figure 1 Schematic diagram of mosquito egg injection.
[0053] Figure 2 Flowchart for screening of gene knockout mosquitoes.
[0054] Figure 3 The peak diagram of the knockout mosquito sequencing and its comparison with the wild-type mosquito sequence. Among them, a is the peak diagram of the single and double peaks of the FO generation chimera sequencing; b is the partial sequence comparison diagram of the FO generation chimera molecular clone sequencing; c is the partial sequence comparison diagram of the F1 generation heterozygous molecular clone sequencing; d is a schematic diagram of the sequence comparison between the MAL1 gene knockout strain mosquito and the wild strain mosquito.
[0055] Figure 4 Flowchart for virus infection of MAL1 knockout mosquitoes and wild-type mosquitoes.
[0056] Figure 5 The changes in viral infection levels in knockout and wild-type mosquitoes after infection with dengue virus. DETAILED DESCRIPTION
[0057] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0058] The sequence information involved in the present invention is as follows:
[0059] AAEL009524,alpha-amylase,MAL1(SEQ ID NO.1)
[0060] MKIFVPLLSFLLAGLTTGLDWWEHGNFYQVYPRSFKDSDGDGIGDLDGVTEKLKYLKDIGMDGVWLSPIFSSPMADFGYDISNFREIQTEYGDLDAFQRLSDKCKQLGLHLILDFVPNHTSDQHEYFKKSVQKDETYKDFYVWH PGVHGPNNTKVPPSNWISVFRGSSWEWNEERQEFYLHQFLKEQPDLNYRNPAVVEEMKNVLRYWLDRGVSGFRIDAVPYLFESDIIDGRYRNEPESRTTDDPENPAYLVHTQTMDQPETYDMIYQWRAVLDEYSKTDNRTRIMMT EGYTSLPKIIEFFGNATANGAQIPFNFEVISNVKKNSTGADFATYVKRWLDAKPANRRSNWVLGNHDNNRLGSRLGENKIDLYNIALQTLPDIAVTYYGEEIGMLDQWIPWNETVDPAACRSDEASYSAYSRDPARTPMQWDSGK NAGFSKAAKTWLPVADNYKTLNVKIQDRARKSHLKIFKKLTKYRKRQILTEGDIDIKVSGENLLVYKRKVDKVGYVVVALNFGTEPVALGLSSLFDRADQRMQVVVVSSNRVSTPDNVWVDVDNYVLIGESGIVLQYLWGKNPIVS
[0061] LOC5572111,probable maltase[Aedes aegypti(yellow fever mosquito)],MAL1(SEQ ID NO.2)
[0062] TTAGCGAACATGGTCATCATTCAACTGACATCGGTTGCTCTAGGCATAGAGTGCACTGATCGGAACAGGCAGA ATG
[0063] Target sequence recognized by sgRNA (SEQ ID NO.3)
[0064] GCTAGGAGGAAGCTTAGAAG
[0065] Nucleotide sequence of sgRNA (SEQ ID NO.4)
[0066] TAATACGACTCACTATAGGCTAGGAGGAAGCTTAGAAGGTTTTAGA GCTAGAAATAGC
[0067] Partial verification sequence of wild-type Aedes aegypti MAL1 gene (SEQ ID NO.5)
[0068] TTAGCGAACATGGTCATCATTCAACTGACATCGGTTGCTCTAGGCATAGAGTGCACTGATCGGAACAGGCAGA ATG AAGATCTTTGTTCCACTTCTAAGCTTCCTCCTAGCAGGACTAACCACCGGGTTGGACTGGTGGGAACATGGAAACTTCTACCAAGTTTACCCAAGATCCTTCAAGGACTCCGACGGCGACGGTATCGGGGATCTGGACGGTAA GATCAGGATCTAAGCTTACAATTTATCATTAAGAATTATTTCTTTCTCTAGGAGTCACCGAAAAGCTGAAATATCTGAAAGACATCGGCATGGACGGAGTTTGGTTGTCACCGATTTTCTCTTCTCCGATGGCTGATTTTGGCT
[0069] Partial verification sequence of knockout Aedes aegypti MAL1 gene (SEQ ID NO.6)
[0070] TTAGCGAACATGGTCATCATTCAACTGACATCGGTTGCTCTAGGCATAGAGTGCACTGATCGGAACAGGCAGCTTCCTCCTAGCAGGACTAACCACCGGGTTGGACTGGTGGGAACATGGAAACTTCTACCAAGTTTACCCAAGATCCTTCAAGGACTCCGACGGCGA CGGTATCGGGGATCTGGACGGTAAGATCAGGATCTAAGCTTACAATTTATCATTAAGAATTATTTCTTTCTCTAGGAGTCACCGAAAAGCTGAAATATCTGAAAGACATCGGCATGGACGGAGTTTGGTTGTCACCGATTTTCTCTTCTCCGATGGCTGATTTTGGCT
[0071] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0072] Aedes aegypti in the following examples were collected in Haikou City, Hainan Province, and propagated in a breeding room.
[0073] Example 1 Construction method of MAL1 gene knockout Aedes aegypti
[0074] 1. sgRNA Preparation
[0075] 1. Design sgRNA target
[0076] The possible DNA sequence of the Aedes aegypti MAL1 gene (Gene ID: 5572111, amino acid sequence see SEQ ID NO.1, nucleotide sequence see SEQ ID NO.2) was obtained from the NCBI database (https: / / www.ncbi.nlm.nih.gov / ), and the sgRNA guide sequence was designed based on the DNA sequence. The target sequence of the sgRNA is as follows:
[0077] sgRNA target sequence: 5'-GCTAGGAGGAAGCTTAGAAG-3' (SEQ ID NO. 3);
[0078] 2. Synthesize sgRNA sequences
[0079] Artificially synthesized sgRNA sequence:
[0080] sgRNA sequence (SEQ ID NO.4):
[0081] TAATACGACTCACTATAGGCTAGGAGGAAGCTTAGAAGGTTTTAGA GCTAGAAATAGC.
[0082] 2. Preparation of MAL1 gene knockout Aedes aegypti
[0083] 1. Preparation before microinjection
[0084] 1) Preparation of RNP complex
[0085] RNP complex: TrueCut TM Cas9 Protein v2 (10 μg / μL) (Invitrogen, Catalog No. 01005198) was mixed with sgRNA solution (solvent: water) to obtain a mixture with a final concentration of sgRNA of 40 ng / ul and a final concentration of Cas9 nuclease of 300 ng / ul.
[0086] The above mixture was mixed and incubated at 37° C. for 15 minutes to obtain a ribonucleoprotein (RNP) complex.
[0087] 2) Preparation of mosquito eggs for injection
[0088] Collect the incompletely developed eggs of Aedes aegypti that have just been laid within 30 minutes, and use a No. 00 hook pen to arrange the eggs neatly, with the end where the gonads are located (the small head end) on the same side.
[0089] Use transparent double-sided tape to transfer and fix the mosquito eggs on a 20×20 cm glass slide and dehydrate for 30-60 seconds. When the mosquito eggs are observed to be slightly concave, add drops of Halocarbon oil 27 (SIGMA, product number H8773) to maintain the humidity of the mosquito eggs.
[0090] 3) Preparation of microinjection needle
[0091] Using Microloader TM The RNP complex in 1) is added to the Femtotip II microinjection needle (Eppendorf, catalog number 5242957000) using a pipette tip (Eppendorf, catalog number 5242956003). The microinjection needle is fixed on a BV-10 needle grinder (SUTTER, catalog number BV10-2300) and the needle tip is lightly ground to open a small opening.
[0092] The opened microinjection needle was mounted on the needle holder of the FemtoJet 4i air pump (Eppendorf, catalog number 5252KN102540), the needle holder was fixed on the robotic arm (Eppendorf, catalog number 5193KN302559) after adjusting the appropriate angle (usually 20-30 degrees), and the microinjection needle was controlled using the TransferMan4r joystick (Eppendorf, catalog number 5193KN302559).
[0093] 2. Mosquito egg microinjection
[0094] Place the mosquito eggs prepared in 2) above under a stereo microscope and adjust the magnification to an appropriate level, usually 100-200 times. Use the joystick to manipulate the microinjection needle and inject the RNP complex into the end of the mosquito egg gonad, preferably when the mosquito egg is slightly bulging but not ruptured. A total of 2244 mosquito eggs were injected, which are the G0 generation. Figure 1 After the injected mosquito eggs are soaked in dechlorinated water, they are gently removed from the double-sided tape with a liner pen and transferred to the soaked thick filter paper to wait for hatching.
[0095] 3. Screening and sequencing verification of MAL1 gene knockout Aedes aegypti
[0096] 1. F0 generation mosquito breeding
[0097] The injected mosquito eggs were placed in a breeding room (relative humidity 75±5%; temperature 28±1℃; day and night time ratio: 14h:10h) for 5 days before hatching. Dechlorinated water was placed in a deep enamel dish, the water was as deep as possible, a little feed was put in, and the thickened filter paper with eggs was immersed in the dish. After complete hatching, the dish was covered and raised. The membrane was scraped once in the morning and evening to keep sufficient feed. A total of 36 (19♀, 17♂, F0 generation) were hatched, with a survival rate of 1.60%. After pupation, the pupae were placed in mosquito breeding tubes and fed with cotton balls soaked in 8% sugar water. After they emerged, the shed pupal skins were taken for corresponding numbers and subsequent testing.
[0098] 2. Design of primers for MAL1 gene amplification
[0099] A pair of MAL1 gene PCR amplification primers were designed based on the DNA sequence of the Aedes aegypti MAL1 gene. The primer sequences are as follows:
[0100] F: 5'-TTCGCGCCACATCGTTATTC-3';
[0101] R: 5'-AGCCAAAATCAGCCATCGGA-3'.
[0102] 3. PCR amplification of wild-type Aedes aegypti MAL1 gene
[0103] The genomic DNA of wild-type Aedes aegypti was extracted (Takara, Catalog No. 9765), and PCR amplification was performed using primers F and R designed in step 2 to obtain PCR products. The PCR reaction system (Takara, Catalog No. RR901A) is shown in Table 1, and the PCR reaction conditions are shown in Table 2.
[0104] Table 1 PCR reaction system
[0105] Components Dosage Premix Taq 12.5μl F 0.5μl R 0.5μl DNA template 2μl dd H2O 9.5μl Total 25μl
[0106] Table 2 PCR reaction conditions
[0107]
[0108] The PCR product with clear and bright bands was sequenced to obtain a partial sequence of the wild-type Aedes aegypti gene. The product was 419 bp in length, of which sequence positions 57-419, a total of 363 bp, were partial MAL1 gene (SEQ ID NO.5).
[0109] 4. Screening and verification of homozygous MAL1 gene knockout strains in Aedes aegypti
[0110] Extract the genomic DNA of the F0 generation knockout Aedes aegypti pupal skin in step 3-1. Because the amount of pupal skin DNA is small, a pair of nested PCR primers are designed based on the MAL1 gene PCR amplification primer FR. The sequences of the nested PCR primers are as follows:
[0111] NestF: 5'-TCCATTGATTAGCGAACATGGT-3';
[0112] NestR: 5'-AGTCCTTGAAGGATCTTGGGT-3'.
[0113] The mutation of the MAL1 gene sequence in the pupal skin of Aedes aegypti was detected by nested PCR amplification. The primers, reaction system and conditions of the first PCR amplification were the same as those in step 2 and 3 of step 3. The nested PCR amplification primer was NestFR, and the first PCR product was diluted 100 times as an amplification template. The reaction system was the same as step 3 of step 3, and the reaction conditions were shown in Table 3.
[0114] Table 3 PCR reaction conditions
[0115]
[0116] The nested PCR products were sequenced. Because the FO generation knockout mosquitoes were chimeras, the sequencing results could not be directly compared with the wild-type Aedes aegypti MAL1 gene sequence. We could first observe whether the sequencing peak graph showed a single-peak and double-peak boundary at the sgRNA target knockout site. If the sequence before the sgRNA target site was normal, the peak graph would be a single peak. If the knockout was successful, the sequence after the sgRNA target site would be disordered, and the peak graph would be an irregular double peak. This would determine whether the mosquito corresponding to the pupal skin was a MAL1 gene knockout mosquito. The gene knockout mosquito screening process is shown in Figure 2 .
[0117] The results showed that a total of 8 mosquitoes may have been successfully knocked out, namely ♀9, ♀10, ♀13, ♀14, ♀15, ♀16, ♀18, and ♂17, with a gene editing rate of 22.22%. The single and double peak boundaries of the sequencing peak graph can be seen Figure 3 a. They were mated with wild-type Aedes aegypti mosquitoes, fed with blood after 3 days, and then eggs were collected after another 3 days. Blood feeding and egg collection can be performed multiple times (G1 generation). At the same time, the PCR product of the pupal skin DNA of one of the ♀15 (F0 generation, chimera) mosquitoes was selected for gel excision recovery (Tiangen Company, item number DP209), and the recovered product was connected to a vector (Quanshijin Company, item number CT101). After plating, a single clone of the bacteria was selected for sequencing, and the sequence was compared to further verify whether it was knocked out. Because the F0 generation is a chimera, the sequencing results of 30 clones of the ♀15 pupal skin DNA showed that some of the single clone sequences had base deletions. The two genotypes had base deletions of 8bp and 11bp, respectively. The sequence comparison is shown in Figure 5. Figure 3 Middle b.
[0118] According to the method in step 3, hatch the G1 generation eggs produced by ♀15 (F0 generation) again, and screen the Aedes aegypti mosquitoes with gene knockout in the F1 generation according to the above nested PCR-sequencing peak diagram-molecular cloning-sequence alignment method, and select the pupal skin DNA of ♀1 (F1 generation, heterozygous) for molecular cloning. Because the F1 generation is heterozygous, the sequencing results of 30 clones show that some of the monoclonal sequences have base deletions, with a deletion of 27bp. The sequence alignment is shown in Figure 3 c. ♀1 (F1 generation) was mated with male wild-type Aedes aegypti mosquitoes and blood-fed several times to collect eggs (G2 generation).
[0119] The G2 generation eggs were hatched again according to the method in step 3, and the pupal skins (F2 generation, heterozygous) were used for sequencing verification again according to the above method. Female Aedes aegypti mosquitoes with base deletions were selected to mate with male Aedes aegypti mosquitoes, and blood was fed multiple times to collect eggs (G3 generation).
[0120] The G3 generation eggs were hatched again according to the method in step 3, and the pupal skins (F3 generation, heterozygotes and homozygotes coexisted) were used for sequencing verification again according to the above method. According to the sequencing results of molecular cloning, homozygous female and male F3 generation Aedes aegypti (all monoclonal sequencing sequences had base deletions) with base deletions were selected for mating, and blood was fed multiple times to collect eggs (G4 generation).
[0121] According to the method in step 3, hatch the G4 generation eggs again to obtain the homozygous Aedes aegypti strain (F4 generation) with MAL1 gene knockout. The sequence is missing 27bp. The sequence of some knockout strains of Aedes aegypti is shown in the following table. Figure 3 Middle d. Feed blood several times to collect eggs and expand the breeding to prepare for subsequent infection verification experiments.
[0122] The only difference between the genome sequences of the knockout mosquito strain and the wild mosquito strain is that a 27bp fragment is deleted (located in the exon, including the promoter) in the MAL1 gene sequence (SEQ ID NO.5). The deleted fragment is located at positions 73-99 of SEQ ID NO.5. The mutated MAL1 gene sequence in the knockout mosquito strain is shown in SEQ ID NO.6 in the sequence table.
[0123] Hereinafter, the MAL1 knockout strain Aedes aegypti is referred to as KO strain, and the wild-type strain Aedes aegypti is referred to as WT strain.
[0124] Example 2 Detection of virus levels after infection of MAL1 gene-knockout Aedes aegypti
[0125] 1. Mosquito virus blood meal infection experiment
[0126] Test mosquito strains: WT strain of Aedes aegypti, KO strain of Aedes aegypti.
[0127] Experimental method: Oral virus blood meal infection experiment was carried out using mosquitoes that were 3-5 days old. After infection, the mosquitoes were fed with cotton balls soaked in 5% sugar water. The mosquito virus infection process is shown in Figure 4 .
[0128] Specific steps:
[0129] 1. Stop supplying sugar water 24 hours before the infection experiment to promote mosquitoes to suck blood quickly when hungry;
[0130] 2. Transfer the mosquitoes that have been deprived of sugar water to the infection laboratory;
[0131] 3. Add 200ul fetal bovine serum to the blood meal cup, then add 4ml fresh sterile decellulose sheep blood, then add an equal volume of dengue virus suspension and mix well;
[0132] 4. Gently unfold the sealing film to simulate the skin and seal the mouth of the blood meal cup. Connect the blood meal cup to a peristaltic pump (one end of which is connected to a 37°C water bath) and place it in the infected mosquito cage.
[0133] 5. After 2 hours of blood supply, use a mosquito aspirator to suck out carbon dioxide to anesthetize the mosquitoes and place them on ice. Select the blood-filled female mosquitoes and raise them separately.
[0134] 2. Virus level detection after infection
[0135] About 30 mosquitoes were dissected at 3, 6, 9 and 12 days after infection to obtain midgut samples, and RNA was extracted for virus detection. The detection kit used was a one-step fluorescent quantitative detection kit (probe method, Quanshijin Company, catalog number AQ211)
[0136] The dengue virus primer probe is as follows (recorded in the literature "Study on co-infection of dengue type 1 virus and dengue type 2 virus in C6 / 36 cells and Aedes albopictus"):
[0137] D2-F:5'-AATTAGAGAGCAGATCTCTGATGAA-3';
[0138] D2-R:5'-AGCATTCCAAGTGAGAATCTCTTTGT-3';
[0139] D2-P:HEX-GCTGTTGCACAGTTGACACGCG-BHQ1.
[0140] Table 4 Reaction system
[0141] Components Dosage 2×PerfectStart*Probe One-Step qPCR SuperMix 10μl TransScripr*Probe One-Step RT / RI Enzyme Mix 0.4μl F(10μM) 0.4μl R(10μM) 0.4μl Probe (1μM) 1μl RNA template 2μl RNase-free Water 5.4μl Total 20μl
[0142] Table 5 Reaction conditions
[0143]
[0144] The results showed that after infection with dengue virus, the infection rate of the midgut of KO strain Aedes aegypti was lower than that of WT strain Aedes aegypti, and the difference in infection rate between the two was statistically significant (P<0.05). Figure 5 shown.
[0145] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. Use of a substance having the gene sequence shown in SEQ ID NO.2 or its homologous sequence knocked out or partially knocked out in the preparation of a product for the prevention and treatment of mosquito-borne infectious diseases.
2. The use according to claim 1, characterized in that: Partial knockout includes knocking out bases 73-99 of the gene sequence shown in SEQ ID NO.2 or its homologous sequence.
3. The use according to claim 1, characterized in that: The substance for knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence includes a CRISPR / Cas system, siRNA, shRNA or a sequence packaged by a lentivirus.
4. The use according to claim 3, characterized in that: The CRISPR / Cas system comprises sgRNA and Cas9 nuclease; the sgRNA is selected from at least one of the following: (1) The sgRNA is designed with the sequence shown in SEQ ID NO.2 or a portion thereof as the target; (2) The sgRNA is designed for the target site shown in SEQ ID NO.3; (3) The sequence of the sgRNA is shown in SEQ ID NO.
4.
5. A drug for mosquito-borne infectious diseases, characterized in that: The mosquito-borne infectious disease drug contains at least one of the following: (1) A substance that knocks out or partially knocks out the gene sequence shown in SEQ ID NO.2 or its homologous sequence; (2) A substance that deletes bases 73 to 99 of the gene sequence shown in SEQ ID NO. 2 or its homologous sequence.
6. The mosquito-borne infectious disease drug according to claim 5, characterized in that: The mosquito-borne infectious disease drug is administered to mosquitoes or mosquito cells.
7. A method for reducing the level of viral infection in mosquitoes or mosquito cells, characterized in that: The method comprises the steps of knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence in mosquitoes or mosquito cells.
8. The method according to claim 7, characterized in that: The method comprises the steps of knocking out bases 73-99 or their homologous sequences in SEQ ID NO.2 in mosquitoes or mosquito cells.
9. A method for constructing a mosquito model or a mosquito cell model with reduced viral infection level, characterized in that: The method comprises the steps of knocking out or partially knocking out the gene sequence shown in SEQ ID NO.2 or its homologous sequence on the mosquito or mosquito cell genome.
10. The construction method according to claim 9, characterized in that: The specific construction method of the mosquito model includes: S1. Using a CRISPR system containing the sgRNA shown in SEQ ID NO.4 to treat mosquito eggs to obtain gene-edited mosquito eggs; S2. Hatching the gene-edited mosquito eggs to obtain parent mosquitoes, hybridizing the parent mosquitoes with wild-type mosquitoes, repeating the process at least once, and obtaining offspring mosquitoes; S3. Crossing the progeny mosquitoes until a knockout homozygote is obtained to obtain the mosquito model.
Citation Information
Patent Citations
Delivery system
US20020124274A1
Cited By
Aedes albopictus aalClk gene and dsRNA and application thereof
CN119979548A
